Details of the Drug Combinations

General Information of This Drug (ID: DMZOLBI)

Drug Name

Carbamazepine DMZOLBI

Synonyms

Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals

Indication

Disease Entry	ICD 11	Status	REF
Epilepsy	8A60-8A68	Approved	[1]
Epilepsy with generalized tonic-clonic seizures	N.A.	Approved	[2]
Focal epilepsy	N.A.	Approved	[2]
Glossopharyngeal neuralgia	N.A.	Approved	[2]
Trigeminal neuralgia	8B82.0	Approved	[2]
Type-1 diabetes	5A10	NDA filed	[3]
Gastric adenocarcinoma	2B72	Phase 3	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dolutegravir + Carbamazepine	DC9AE80	Dolutegravir	Infection, Human Immunodeficiency Virus	[5]
Eslicarbazepine acetate + Carbamazepine	DCSYV4G	Eslicarbazepine acetate	Epilepsy	[6]
Pomalidomide + Carbamazepine	DCCDX2V	Pomalidomide	Pharmacology, Clinical	[7]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5339).
2	Carbamazepine FDA Label
3	Clinical pipeline report, company report or official report of Lundbeck.
4	ClinicalTrials.gov (NCT01128959) Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy. U.S. National Institutes of Health.
5	ClinicalTrials.gov (NCT01967771) Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects
6	ClinicalTrials.gov (NCT02284854) Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine
7	ClinicalTrials.gov (NCT01707407) A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects